Drug Trial Radar · NCT00442936
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Last checked: Nov 20, 2026Latest source record: Oct 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,380
Actual
Start
Feb 15, 2007
Primary completion
Oct 2, 2007
Study completion Oct 2, 2007
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine. This study was conducted as a "triple-dummy" design; for each dose of study drug, participants each received 3 forms of study drug (2 capsules of active and/or placebo and 1 tablet of active and/or placebo) and were instructed to take one of each form of study drug at dosing time. The primary hypotheses of this study are that telcagepant is superior to placebo in Pain Freedom at 2 Hours Post-Dose, Pain Relief at 2 Hours Post-Dose, Absence of Photophobia at 2 Hours Post-Dose, Absence of Phonophobia at 2 Hours Post-Dose and Absence of Nausea at 2 Hours Post-Dose.
Conditions
- Migraine
Interventions
Telcagepant potassium 150 mgDrug
Telcagepant 150 mg liquid-filled soft gel capsules
Telcagepant potassium 300 mgDrug
Telcagepant 300 mg liquid-filled soft gel capsules
Zolmitriptan 5 mgDrug
Zolmitriptan 5 mg tablets
Placebo to telcagepant 150 mgDrug
Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
Placebo to tecagepant 300 mgDrug
Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
Placebo to zolmitriptan 5 mgDrug
Placebo to match zolmitriptan 5 mg tablets
Rescue medicationDrug
If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Pain Freedom (PF) at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Number of Participants With Pain Relief (PR) at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Number of Participants With Absence of Photophobia at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Number of Participants With Absence of Phonophobia at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Number of Participants With Absence of Nausea at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Number of Participants Who Experience At Least One Adverse Event (AE)Time frame: Up to 14 days after last dose of study drug
- Number of Participants Who Discontinue Study Drug Due to an AETime frame: Up to 48 hours after first dose of study drug
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.